Literature DB >> 11907489

Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.

Irmgard Tegeder1, Lutz Bräutigam, Maurizio Podda, Silke Meier, Roland Kaufmann, Gerd Geisslinger, Marcella Grundmann-Kollmann.   

Abstract

BACKGROUND: The combination of 8-methoxypsoralen with ultraviolet A exposure (PUVA therapy) is a standard treatment for a variety of dermatoses. The following three variants have been described: oral, bath, or cream PUVA. To achieve optimal therapeutic effects, ultraviolet A irradiation should be performed at the time of maximum photosensitivity, that is, at the time of maximum 8-methoxypsoralen tissue concentrations.
METHODS: To further specify this point of time, we assessed the concentration-time courses of 8-methoxypsoralen in the skin after oral, bath, and cream administration of 8-methoxypsoralen in a 3-way crossover microdialysis study of 8 healthy subjects.
RESULTS: Tissue concentrations after oral administration of 0.6 or 1 mg/kg 8-methoxypsoralen were low (peak plasma concentration range, 1.7-6.6 ng/ml) compared with topical administration for which maximum concentrations of 200 to 520 ng/ml and 720 to 970 ng/ml were achieved with 0.1% 8-methoxypsoralen cream and 3 mg/L 8-methoxypsoralen bath, respectively. Plasma concentrations after oral 8-methoxypsoralen, however, were up to 1000-fold higher than those found after topical application. With both topical applications, the tissue peak concentration uniformly occurred in the first 20 minutes after the end of the application time. In contrast, the time to reach the tissue peak concentration after oral administration ranged from 1 to 4 hours.
CONCLUSIONS: The time course of tissue concentrations corresponds closely with the time course of minimal phototoxic doses found in previous studies. Because tissue concentrations after topical administration of 8-methoxypsoralen (bath and cream) were high compared with plasma concentrations and because they were less variable and occurred at better predictable time points than those after oral administration, we suggest that topical PUVA is superior to systemic PUVA, at least from a pharmacokinetic point of view.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907489     DOI: 10.1067/mcp.2002.121908

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  [New aspects in uv and photochemotherapy].

Authors:  M Grundmann-Kollman; A Tanew
Journal:  Hautarzt       Date:  2004-12       Impact factor: 0.751

Review 2.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Assessment of topical bioequivalence using dermal microdialysis and tape stripping methods.

Authors:  Tuba Incecayir; Ilbeyi Agabeyoglu; Ulver Derici; Sukru Sindel
Journal:  Pharm Res       Date:  2011-04-16       Impact factor: 4.200

Review 4.  In vivo methods for the assessment of topical drug bioavailability.

Authors:  Christophe Herkenne; Ingo Alberti; Aarti Naik; Yogeshvar N Kalia; François-Xavier Mathy; Véronique Préat; Richard H Guy
Journal:  Pharm Res       Date:  2007-11-06       Impact factor: 4.200

5.  Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.

Authors:  Chao Wang; Xiaokui Huo; Xiangge Tian; Min Xu; Peipei Dong; Zhilin Luan; Xiaobo Wang; Baojing Zhang; Bo Zhang; Shanshan Huang; Sa Deng; Xiaochi Ma
Journal:  Br J Pharmacol       Date:  2016-10-10       Impact factor: 8.739

6.  Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.

Authors:  Jian Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2006-09-26       Impact factor: 4.849

7.  Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.

Authors:  Marcella Grundmann-Kollmann; Maurizio Podda; Lutz Bräutigam; Katja Hardt-Weinelt; Ralf J Ludwig; Gerd Geisslinger; Roland Kaufmann; Irmgard Tegeder
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

8.  Intake of Furocoumarins and Risk of Skin Cancer in 2 Prospective US Cohort Studies.

Authors:  Weiyi Sun; Megan S Rice; Min K Park; Ock K Chun; Melissa M Melough; Hongmei Nan; Walter C Willett; Wen-Qing Li; Abrar A Qureshi; Eunyoung Cho
Journal:  J Nutr       Date:  2020-06-01       Impact factor: 4.798

9.  Transcutaneous sampling of ciprofloxacin and 8-methoxypsoralen by electroporation (ETS technique).

Authors:  Srinivasa M Sammeta; Siva Ram K Vaka; S Narasimha Murthy
Journal:  Int J Pharm       Date:  2008-11-05       Impact factor: 5.875

10.  A quantitative mass spectrometry-based approach for assessing the repair of 8-methoxypsoralen-induced DNA interstrand cross-links and monoadducts in mammalian cells.

Authors:  Shuo Liu; Yinsheng Wang
Journal:  Anal Chem       Date:  2013-07-03       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.